The most common include mild to moderate pain at the injection site, fatigue, and headaches. Most side effects are mild to moderate in severity and are gone within a few days. An interim analysis of study data showed a potential efficacy of 91.3% in preventing symptomatic infection within seven days of a second dose and no serious safety concerns. Ĭlinical trials began in April 2020 by November 2020, the vaccine entered phase III clinical trials, with over 40,000 people participating. Initial advice indicated that vaccination required two doses given 21 days apart, but the interval was later extended to up to 42 days in the US, and up to four months in Canada. It is composed of nucleoside-modified mRNA (modRNA) encoding a mutated form of the full-length spike protein of SARS-CoV-2, which is encapsulated in lipid nanoparticles. The vaccine is given by intramuscular injection. It is authorized for use in people to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. For its development, BioNTech collaborated with American company Pfizer to carry out clinical trials, logistics, and manufacturing. Representatives from both institutions took part of a training at the World Health Organization mRNA global hub, Afrigen Biologics, to accelerate the development of the technology in the region.The Pfizer–BioNTech COVID-19 vaccine ( INN: tozinameran), sold under the brand name Comirnaty, is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. “Canada is pleased to support PAHO’s innovative work to strengthen vaccine production capacities in Latin America and the Caribbean and to deepen our partnership on this critical issue for the region,” Ambassador Hugh Adsett, Permanent Representative of Canada to the Organization of American States said.īuilding on existing capacities in the region, the PAHO initiative will support training and technology transfer, strengthen regional value chains to source the necessary components for vaccine manufacturing, and bolster regulatory systems and enabling functions for vaccines production.Īs part of the PAHO effort, in September 2021 Bio-Manguinhos/FIOCRUZ in Brazil and Sinergium Biotech in Argentina were selected to be part of a technology transfer initiative for the development and production of mRNA-based vaccines in the region.
“This disparity underscored the need to invest in efforts to diversify the production of vaccines and their components across countries,” the PAHO Director said, while taking advantage of new health technologies, such as messenger RNA (mRNA) vaccines that can be used beyond COVID-19. The COVID-19 health crisis uncovered major rifts in access to health care and exposed the region’s high dependence on imports for vaccines, medicines and other medical supplies.Ĭountries with local production capacity were the first to benefit from COVID-19 vaccines, but much of Latin America and the Caribbean had to wait for these to become available from centralized external manufacturers, leading to significant delays in the rollout of campaigns to protect lives.
:max_bytes(150000):strip_icc()/ScreenShot2020-05-18at3.49.23AM-25eec9931f974b92932bddad81389bcc.png "vaccine production capacity us")
“We thank the Government of Canada for this generous and timely contribution, which will be crucial in making the region better prepared for future challenges,” PAHO’s Director Carissa F. Launched in 2021, the PAHO Regional Platform to Advance the Manufacturing of COVID-19 Vaccines and other Health Technologies in the Americas aims to increase the region’s ability to respond more quickly and autonomously to health emergencies and to improve access to much needed vaccines, medicines, and other medical supplies. Washington, D.C., Novem(PAHO) – The Government of Canada has announced a $15 million Canadian dollar contribution (equivalent to US$ 11.2 million) towards a Pan American Health Organization (PAHO) initiative to increase vaccine production capacities in Latin America and the Caribbean.
0 kommentar(er)
